BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 17, 2009
 |  BC Week In Review  |  Company News  |  Other News

Mylan, Pfizer, William J. Clinton Foundation infectious news

The foundation's HIV/AIDS Initiative announced agreements with Mylan and Pfizer to offer more affordable treatments for patients in the developing world with drug-resistant HIV. Pfizer agreed to sell generic rifabutin to treat tuberculosis (TB) in patients receiving second-line antiretroviral therapy for HIV/AIDS at $1 per 150 mg dose, or $90 for a full course of treatment over six months. The price is a 60% discount and is available in developing markets in Africa, Asia,...

Read the full 349 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >